STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Adipotide

Also known as

FTPP · Fat-Targeted Proapoptotic Peptide · FTTP (common misspelling of FTPP) · Prohibitin-TP01 · Prohibitin-targeting peptide 1 · TP01 · CKGGRAKDC-GG-D(KLAKLAK)2 · Arrowhead Adipotide / Ablaris adipotide (historical development)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic SubQ Metabolic / fat-loss peptides

Whole-body — people treat this as circulating, not a local pin.

What people say Adipotide is a fat-vessel-targeting peptidomimetic discussed for fat loss, with striking animal results and prominent kidney warnings. It is not a GLP-1, proven human weight-loss treatment or local spot-fat injection. Doses people talk about
Community fixed-amount charts250–1,000 mcg SC daily

Vendor/forum figures; about 1 mg/day also appears in personal logs, sometimes with AOD-9604 300 mcg/day. Co-use does not validate the amount.

Historical human trial design0.03 mg/kg SC daily for 28 days

Registry starting dose for first-in-human dose finding, not completed MTD or efficacy results.

Primate fixed-dose study0.43 mg/kg SC daily for 28 days

Obese rhesus, n=10 treated / n=5 control; kidney findings accompany the animal efficacy context. Not a human conversion.

These are discussion and research amounts, not a safe starting ladder. The original high-dose misuse and kidney warnings remain in full.

Half-life & effect duration

Half-life in the body
  • Community / secondary estimateAbout 2–4 hours
Felt duration people report
  • Hunger · with AODAbsent from 6 AM through an 11:30 AM update in one account
  • Local reactionsBurning or itching for minutes; sometimes irritation through the day
  • Other resultsWeak changes before a diet change in another log
Timing context & sources
How it may feel Accounts conflict: one AOD-combination log claimed appetite and weight changes, while another described local burning/itching and little progress before a diet change. Co-use, diet and unverified products prevent clean attribution.
Cycles people discuss 28-day courses recur in community charts and the historical study design. The primate 28-day recovery observation was not proof of a safe human washout; repeat or back-to-back courses lack an established safety basis in these notes. Timing Once-daily SC appears in the animal and planned human designs and in community charts. Effects tracked over weeks after stopping are not a measured parent half-life; appetite impressions are also distinct from renal warning signs. Stacks AOD-9604 co-logs exist, but the combination confounds benefits and safety. GLP-1s, tesamorelin and other fat-loss compounds are also compared or co-mentioned—not established safe Adipotide stacks. Watch for Kidneys (headline animal tox): Dose-dependent proximal-tubule injury — single-cell necrosis, degenerative/regenerative tubular changes — primary safety signal across rhesus GLP and efficacy work.
Related
AOD-9604TesamorelinSemaglutideTirzepatide5-Amino-1MQ

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A human parent half-life is not established by the checked evidence.

NCT01262664 lists PK sampling but has no posted results. The accessible original primate abstract reports efficacy and renal findings, not a half-life.

The legacy 2–4 h secondary claim remains identified as such. Neither that claim nor weeks of post-stop animal change supplies a measured human clock; primary full text was inaccessible.

  • Prohibitin-targeting peptide 1 — NCT01262664 (opens in a new tab)Actual ClinicalTrials.gov API v2 record: statusModule, armsInterventionsModule and outcomesModule; last update Jan. 4, 2019, hasResults:false.Terminated per PI request. Starting dose and PK sampling times are study design, not observed half-life, completed MTD, efficacy or a public safety results table.
  • Barnhart et al. — adipotide in obese monkeys (opens in a new tab)Original abstract accessed through Europe PMC core record, PMID 22072637: white-fat targeting, imaging and renal proximal-tubule findings.Abstract only. PMC full text returned a browser challenge; Europe PMC full-text endpoint returned no content; a PDF mirror returned 429. Abstract supports animal target and renal signal, not an exact parent half-life or all detailed legacy study figures.

Felt duration people report

No dependable single-dose benefit window is established by the inspected logs.

One AOD-combination poster reported no hunger from a 6 AM dose through an 11:30 AM update. Another recorded local burning/itching for minutes, sometimes irritation through the day, and weak pre-diet-change results.

An observation ending at 11:30 AM does not establish a 5.5-hour duration. Local irritation is not fat-loss duration; one log's inconsistent units cannot support dose conclusions.

  • Adipotide experiment — completed self-log (opens in a new tab)Actual ChrisBGood post dated Feb. 25, 2026, internal daily log Jan. 27–Feb. 23: days 1, 3, 9, 20 and final day-28 result.Self-report on Tirzepatide with a late dietary cut. Dose text inconsistently equates syringe units, mg and mg/kg; it is not usable dose evidence. Local sensations and the author's weak/null pre-cut result are reports, not verified product effects.
  • Adipotide and AOD 9604 — experience and updates (opens in a new tab)Actual TPTPB41 opening post Jan. 25, 2024 (6 AM co-dosing, observation to 11:30 AM), one-, two- and three-week updates and later post-stop update.AOD-9604, keto and OMAD confound attribution. Claimed appetite and weight changes are not measured drug residence. Later update contains a disputed calendar year; no exact calendar inference is adopted.

What people say 15

  • Community logs: Sparse and confounded; hype often maps primate 4-week numbers onto gray-market vials; many caution that kidney risk dominates any ‘benefit’ talk. forum
  • Mouse weight (Kolonin-era): Diet-induced obese mice often cited ~30% body-weight reduction over ~4 weeks daily dosing; lean mice generally did not show the same weight loss. animal
  • Primate weight (fixed dose): Obese rhesus at 0.43 mg/kg SC daily × 28 days — average ~10.6% body-weight loss; individual range about −7.4% to −14.7% vs small control swings. animal
  • Primate BMI / girth: Same fixed-dose cohort — average BMI ~−10% and abdominal circumference ~−8.4% by end of treatment. animal
  • DEXA fat mass: Treated rhesus total body fat fell ~38.7% from baseline to end of recovery window vs ~14.8% in saline controls (weekly DEXA subset). animal
  • MRI white-fat volume: Abdominal white-adipose volume down ~17.5% at end of treatment and ~27% by end of recovery vs baseline in treated animals. animal
  • Visceral + subcutaneous: Imaging write-ups describe both visceral and subcutaneous abdominal white fat falling — not only scale weight. animal
  • Insulin resistance: Fixed-dose treated monkeys — insulinogenic index average ~−48.5% vs control rise; insulin AUC after IVGTT down ~36% vs controls. animal
  • Dose-finding insulin: Escalating-dose obese monkeys also cut insulin AUC roughly ~60% in the two treated animals after multi-week courses. animal
  • Early metabolic lag: Secondary summaries and rodent work often claim glucose/insulin shifts within days, sometimes before large scale moves. animal
  • Appetite contrast vs orlistat-class: Primates stayed interactive; no classic nausea/food-aversion syndrome reported; chow biscuits fell while enrichment treats often still eaten. animal
  • Lipids / FFA: Cholesterol/TG panels stayed largely normal; free fatty acids trended down during treatment rather than a ‘lipid flood’ story. animal
  • No hepatic steatosis signal: Histology packages reported no abnormal ectopic fat accumulation (including liver) in the primate safety sets discussed. animal
  • Lean-animal selectivity: Lean rhesus at therapeutic-range doses did not show the obese-animal weight loss — framed as obesity-preferential vascular targeting. animal
  • Human claims: Not settled — Phase 1 discontinued without public MTD, PK, weight, or safety tables. trial

Doses people talk about 20

  • Community fixed-mcg band: Vendor/protocol blogs commonly circulate ~250–1,000 mcg SC daily for ‘research’ discussion. forum
  • Community conservative mg/kg chart: Some peptide-site write-ups claim daily dose ‘should not exceed’ ~0.01 mg/kg (~4.53 mcg/lb) SC for up to ~28 days — forum/vendor conservatism, not a completed human MTD. forum
  • Example community weight chart (0.01 mg/kg logic): Roughly ~455–680 mcg (100–150 lb), ~685–905 mcg (151–200 lb), ~910–1,150 mcg (201–250 lb) daily × ≤28 days appears on third-party dosage pages. forum
  • Forum ‘about 1 mg’ lore: Bodybuilding discussion often treated ~1 mg/day as a more typical research-chemical mention vs extreme multi-mg misuse stories. forum
  • High-end abuse anecdote: Public Bostin Loyd interviews describe using ~5 mg/day (a full common vial size daily) and later kidney failure — widely cited as a cautionary outlier, not a protocol. anecdote
  • Reddit-style logs: Occasional reports of ~1 mg/day adipotide ± AOD-9604 ~300 mcg/day; confounded, short, and not trial data. anecdote
  • Unit conversion trap: 0.43 mg/kg in a 10 kg monkey is multi-mg absolute; naive human ‘same mg/kg’ math produces large absolute doses that community risk posts explicitly warn against. forum
  • No oral / nasal research product standard: Development and community discussion assume injectable peptide, not capsules or sprays. forum
  • Framing: Ranges below come from animal papers, planned Phase 1 design notes, vendor/community charts, and forum anecdotes — research/education only, not advice or prescriptions. forum
  • Phase 1 design (planned): Once-daily SC × 28 days; up to five ascending dose cohorts of three participants; MTD / PK / weight secondary measures in castrate-resistant prostate cancer (NCT01262664). trial
  • Injection volume math: Fixed-dose primate work kept injectate roughly ~150–300 μL by adjusting concentration; community vials often force insulin-syringe unit math from 5–10 mg lyophilized fills. animal
  • Frequency: Once-daily SC dominates animal protocols, planned Phase 1, and forum charts; EOD/weekly schedules are not the literature standard. trial
  • Mouse proof-of-concept: Daily injections for ~28 days produced the classic ~30% obese-mouse weight reduction; specific mouse mg/kg numbers vary by write-up and are not a human protocol. animal
  • Primate dose-finding ladder: Obese rhesus escalating SC daily through 0.10 → 0.25 → 0.43 → 0.75 mg/kg (steps roughly every 2 weeks; final step longer) — dose-dependent weight/BMI/girth drops. animal
  • Primate optimal fixed dose: 0.43 mg/kg SC once daily identified as efficacy/tox balance in spontaneously obese rhesus; used for the n=10 treated / n=5 control 28-day study. animal
  • Primate GLP lean band: Lean rhesus safety arms at 0.25, 0.43, and 0.75 mg/kg SC daily × 28 days; weight loss not the lean-animal story at therapeutic-range doses. animal
  • High single-dose tox note: Class/single-dose work in cynomolgus macaques reported no lethality at single doses up to 100 mg/kg (~orders of magnitude above the therapeutic daily figure) — not a chronic use guide. animal
  • BSA scaling talk: Authors argued optimal daily dose scaled with body-surface-area changes mouse → rat → monkey; raw mg/kg copy across species is not 1:1. animal
  • Phase 1 starting dose (design): The NCT01262664 registry specifies 0.03 mg/kg SC daily as the starting dose for a 28-day first-in-human dose-finding course. This is a planned-study amount, not a completed MTD or a community dosing recommendation. trial
  • No public human dose–response: Trial terminated; no published cohort results, so community fixed-mg charts are extrapolations, not labeled clinical dosing. trial

How it may feel 8

  • Week 1: Community expectations for visible fat dump are often unrealistic; primate efficacy was multi-week, not day-one. forum
  • Human subjective logs: Sparse reports still attract animal 4-week expectations and Bostin Loyd kidney-caution discussion. TPTPB41 reported appetite suppression and weight loss while also using AOD-9604, keto and OMAD; ChrisBGood described repeated local irritation and little progress before a late dietary cut while on Tirzepatide. Neither isolates Adipotide or establishes a dependable benefit window. forumanecdote
  • Days 1–3: Animal work tracked labs and imaging over weeks; it cannot establish the absence of a subjective stimulant high in people. Secondary write-ups sometimes flag early metabolic lab shifts before large scale change. Human local sensations belong to separate self-reports. animal
  • Weeks 2–4: Main documented efficacy window — ~28-day daily SC courses for weight, girth, DEXA/MRI fat, and insulin metrics in rhesus. animal
  • During dosing labs: Creatinine / urine (protein, glucose) can move mid-course at efficacious primate doses — research discussion treats renal panels as the real-time red-flag track, not waist photos alone. animal
  • Food intake (animals): Treated obese monkeys reduced biscuit intake over time while enrichment foods often continued; not a classic ‘food aversion’ profile. animal
  • After last dose (animals): Body weight, BMI, and circumference kept falling for ~2–3 more weeks, then began reversing in the 4-week recovery window. animal
  • Recovery renal: Most serum/urine tubular signals reversed within ~28 days off drug; occasional residual creatinine or glucosuria noted in individual monkeys at recovery end. animal

Cycles people discuss 8

  • Why short courses dominate discussion: Dose-dependent proximal-tubule injury makes multi-month unsupervised daily runs a major caution theme. forum
  • Template length: Daily SC × ~28 days is the dominant length in mouse, obese-rhesus efficacy, lean-rhesus GLP, and planned Phase 1 designs. trial
  • Primate recovery block: Fixed-dose rhesus used 28 days on + 28 days recovery observation — weight/fat metrics lagged after stop then partially rebounded. animal
  • Dose-finding longer run: Initial obese-rhesus escalation ran multi-week steps totaling ~9 weeks of daily dosing in the small dose-ladder cohort before recovery. animal
  • One-course development intent: Clinical design was single 28-day MTD-finding cycle in advanced prostate-cancer patients, not open-ended lifestyle use. trial
  • Off periods / lab-driven stops: Animal renal signals (creatinine, proteinuria, glucosuria) often improved after discontinuation — drives community ‘hard stop + labs’ talk. animal
  • Re-challenge / stacked cycles: Human multi-cycle safety not established after discontinuation; repeating 28-day blocks back-to-back is speculation, not a studied schedule. trial
  • No load/maintain ladder in literature: Unlike some peptides, published work is fixed daily mg/kg or planned human cohort escalation — not a bodybuilding load→cruise model. animal

Timing 8

  • Vendor / secondary half-life talk: Some research-chemical write-ups claim ~2–4 hour plasma half-life with longer tissue-level effects — treat as secondary/community claim, not a labeled PK table. forum
  • Practical ‘timing endpoints’: Community risk talk prioritizes serial creatinine/BUN/urinalysis over chasing peak plasma levels. forum
  • Human t½: The checked trial registry has no posted results or measured human half-life; its PK sampling times are a plan, not an estimate. The accessible primate abstract also supplies no parent-plasma half-life. A human estimate remains unresolved in this review. trial
  • Why daily anyway: Primate efficacy and planned Phase 1 used once-daily SC for weeks regardless of short circulating presence assumptions. trial
  • Downstream fat timing: Vessel-loss and fat-pad changes are different endpoints from circulating parent peptide. The earlier monkey notes describe changes continuing for days–weeks after the last dose; that does not establish a short plasma half-life or a human duration of action. animal
  • Post-dose lag (animals): Weight, BMI, and circumference kept falling ~2–3 weeks after cessation before recovery rebound. animal
  • Metabolic lead time: Insulin/glucose-handling improvements were measurable by end of 28-day courses; some summaries claim early-week metabolic shifts. animal
  • Renal clearance mechanism talk: Literature discusses D-amino acid oxidase acting on the D(KLAKLAK)2 moiety and possible competition with creatinine tubular handling — mechanistic framing for kidney signals, not a dosing calculator. animal

More on what it is 7

  • What it is: Synthetic peptidomimetic CKGGRAKDC-GG-D(KLAKLAK)2 — a fat-vessel homing sequence fused to a mitochondrial-disrupting proapoptotic domain; also called FTPP / Prohibitin-TP01. animal
  • Why people care: ‘Targeted fat-vessel kill’ story from obese-mouse ~30% weight cuts and rhesus monkey papers (~11% weight / large fat-volume drops in ~28 days), not a GLP-1 appetite drug. animal
  • Mechanism talk: CKGGRAKDC binds cell-surface prohibitin (with ANXA2) on white-fat endothelium → internalization → D(KLAKLAK)2 disrupts mitochondria → endothelial apoptosis → vessel collapse → white adipocyte ischemia/clearance. animal
  • Evidence honesty: Strong rodent + Old World primate papers; human Phase 1 (NCT01262664) started 2012 at MD Anderson then terminated without public efficacy/safety package. trial
  • Not: FDA-approved fat drug, completed human efficacy program, oral fat-loss product, or a local ‘spot reduce’ injection. trial
  • Development path: MD Anderson discovery lineage (Kolonin / Arap / Pasqualini); Arrowhead / Ablaris advanced IND-era obesity program, then abandoned clinical push. trial
  • White vs brown: Preclinical framing is white adipose vasculature; brown fat is described as relatively spared in rodent write-ups. animal

Stacks 11

  • Standalone-use discussion (risk-aware): Cautious threads discuss keeping adipotide alone while following kidney labs so side effects are less confounded. This is an attribution concern, not a claim that solo use is safe or an instruction to begin. forum
  • Vs AOD-9604: Common neighbor comparison — AOD framed as gentler lipolytic fragment; adipotide as vessel-kill; sometimes sequential or same-cut discussion, rarely formal ratio stacks. forum
  • Vs Frag 176-191: Same ‘fat peptide cabinet’ talk as AOD cousin; mechanism still not adipotide’s vascular apoptosis path. forum
  • AOD co-logs: Anecdotal same-period use (e.g. ~1 mg adipotide + ~300 mcg AOD) appears in forums — confounded, not a studied combination. anecdote
  • Vs GLP-1 / dual / triple agonists: More compared than stacked (sema / tirz / reta). GLP-1s have large human datasets; adipotide does not — dual use poorly documented and adds polypharmacy risk. forum
  • Vs cardarine / GW / metabolic small molecules: Named in the same ‘cut stack brainstorm’ lists; no quality evidence for combined safety. forum
  • Vs tesamorelin / GH secretagogues: Visceral-fat or recomp neighbors in conversation; different mechanisms and side profiles. forum
  • Vs 5-Amino-1MQ / BAM15: Research-fat niche comparisons (NNMT / mitochondrial uncoupling talk) rather than fixed-ratio protocols. forum
  • Avoid multi-research-agent cocktails: Stacking several experimental injectables hides renal signals and confounds labs. forum
  • Non-drug co-factors: Caloric deficit, resistance training, steps, sleep, and aggressive hydration are named whenever scale change is discussed. forum
  • No standard ‘Wolverine/GLOW-style’ ratio: Adipotide is a single molecule, not a named multi-peptide blend with fixed parts. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 17

  • Bostin Loyd anecdote: Public interviews describe ~5 mg/day use, injection near lower back/chest, later stage-5 kidney disease narrative; causation confounded by polypharmacy/steroids but creatinine reportedly rose after adipotide start — dominant cautionary lore. anecdote
  • Source / identity risk: Gray-market purity, sequence authenticity, and fill accuracy unverified; mislabeling multiplies dosing error risk. forum
  • Metabolic reserve / adipokine talk: Theoretical concern that destroying large white-fat mass could perturb hormone signaling — not a completed long-term human dataset. forum
  • Big picture: Fat-loss animal numbers sit next to the same literature’s kidney dose-dependence; risk-aware discussion treats renal monitoring as non-optional if the compound is even researched. forum
  • Kidneys (headline animal tox): Dose-dependent proximal-tubule injury — single-cell necrosis, degenerative/regenerative tubular changes — primary safety signal across rhesus GLP and efficacy work. animal
  • Creatinine up, BUN often not matching: Slight-to-moderate creatinine rises at doses >~0.25 mg/kg SC without commensurate BUN rise; authors discuss tubular handling / D-amino acid oxidase metabolism of D(KLAKLAK)2. animal
  • Urine findings: Dose-linked mild-to-marked glucosuria, mild-to-moderate proteinuria, transitional/renal epithelial cells. animal
  • Electrolytes: Mild-to-moderate time- and dose-dependent decreases in serum phosphorus and potassium reported in treated monkeys. animal
  • Reversibility (animals): Most serum/urine changes reversed within ~28 days off drug; residual creatinine or glucosuria in occasional individuals at recovery end. animal
  • Dehydration / polyuria: Increased urine output and mild dehydration noted especially at higher doses — compounds renal stress if fluids lag. animal
  • Therapeutic window talk: Efficacy doses sit near doses that move renal markers — narrow margin is a repeated community and paper theme. animal
  • Phase 1 stopped: Human first-in-man dose-finding (prostate-cancer population) terminated per PI request; no full public safety package. trial
  • Pre-existing CKD / low GFR: Trial eligibility required adequate renal function (e.g. creatinine ≤1.5× ULN or CrCl ≥60 mL/min and protein limits); community treats impaired kidneys as hard avoid. trial
  • Not GI-class risk: Low nausea story in primates ≠ low risk — renal endpoints dominate, unlike GLP-1 GI sides. animal
  • Injection site: Local irritation possible; primate methods rotated trunk sites. animal
  • Ectopic fat fear (addressed in animals): Rapid fat kill raised lipid-redistribution concerns; primate panels did not show hepatic steatosis or arterial lipid dumps in the reported windows. animal
  • Pregnancy / unknown populations: No meaningful human safety characterization outside the terminated oncology Phase 1 design. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →